These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 31112621)

  • 21. The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in
    Moore JE; Millar BC; Ollman-Selinger M; Cambridge L
    Respir Care; 2021 Sep; 66(9):1446-1457. PubMed ID: 34031222
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
    Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
    Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients].
    Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ
    Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis.
    Guy EL; Bosomworth M; Denton M; Conway SP; Brownlee KG; Lee TW
    J Cyst Fibros; 2010 Jul; 9(4):292-5. PubMed ID: 20427245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhaled antibiotic therapy in evidence: what delivery device?
    Dennis JH; Pieron CA
    J Cyst Fibros; 2002 Dec; 1(Suppl 2):209-14. PubMed ID: 15463837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition.
    Coates AL; Dinh L; MacNeish CF; Rollin T; Gagnon S; Ho SL; Lands LC
    J Aerosol Med; 2000; 13(3):169-78. PubMed ID: 11066020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tobramycin inhalation powder in cystic fibrosis patients: response by age group.
    Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M
    Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
    Al-Aloul M; Nazareth D; Walshaw M
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems.
    Mashat M; Clark BJ; Assi KH; Chrystyn H
    Pulm Pharmacol Ther; 2016 Apr; 37():37-42. PubMed ID: 26747025
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer.
    Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW
    Int J Pharm; 1999 Nov; 189(2):215-25. PubMed ID: 10536250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Timing of inhaled tobramycin affects assessment of intravenous tobramycin pharmacokinetic monitoring.
    Stenbit AE; Bullington WM; Heh JL; Flume PA
    J Cyst Fibros; 2013 Jul; 12(4):403-6. PubMed ID: 23266092
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Administration of aerosolized antibiotics in cystic fibrosis patients.
    Moss RB
    Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhalation of tobramycin in patients with cystic fibrosis: comparison of two methods.
    Dopfer R; Brand P; Müllinger B; Hunger T; Häussermann S; Meyer T; Scheuch G; Siekmeier R
    J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 1):141-54. PubMed ID: 18204125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal evaluation of compressor/nebulizer performance.
    Awad S; Williams DK; Berlinski A
    Respir Care; 2014 Jul; 59(7):1053-61. PubMed ID: 24149670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis.
    Clavel A; Boulaméry A; Bosdure E; Luc C; Lanteaume A; Gorincour G; Stremler-Lebel N; Sarles J; Andrieu V; Dubus JC
    J Cyst Fibros; 2007 Apr; 6(2):137-43. PubMed ID: 16839826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis.
    Geller DE; Pitlick WH; Nardella PA; Tracewell WG; Ramsey BW
    Chest; 2002 Jul; 122(1):219-26. PubMed ID: 12114362
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.
    Prayle AP; Jain K; Touw DJ; Koch BC; Knox AJ; Watson A; Smyth AR
    J Cyst Fibros; 2016 Jul; 15(4):510-7. PubMed ID: 26282839
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aerosolized antibiotics in cystic fibrosis: an update.
    Fiel SB
    Expert Rev Respir Med; 2014 Jun; 8(3):305-14. PubMed ID: 24838090
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sinonasal inhalation of tobramycin vibrating aerosol in cystic fibrosis patients with upper airway Pseudomonas aeruginosa colonization: results of a randomized, double-blind, placebo-controlled pilot study.
    Mainz JG; Schädlich K; Schien C; Michl R; Schelhorn-Neise P; Koitschev A; Koitschev C; Keller PM; Riethmüller J; Wiedemann B; Beck JF
    Drug Des Devel Ther; 2014; 8():209-17. PubMed ID: 24596456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.